129 related articles for article (PubMed ID: 35171499)
41. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research.
Berardo C; Di Pasqua LG; Cagna M; Richelmi P; Vairetti M; Ferrigno A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348908
[TBL] [Abstract][Full Text] [Related]
42. Clinical characteristics of non-alcoholic fatty liver disease in Chinese adult hypopituitary patients.
Yuan XX; Zhu HJ; Pan H; Chen S; Liu ZY; Li Y; Wang LJ; Lu L; Yang HB; Gong FY
World J Gastroenterol; 2019 Apr; 25(14):1741-1752. PubMed ID: 31011258
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of diacerein in reducing liver steatosis and fibrosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: A randomized, placebo-controlled trial.
Leite NC; Viegas BB; Villela-Nogueira CA; Carlos FO; Cardoso CRL; Salles GF
Diabetes Obes Metab; 2019 May; 21(5):1266-1270. PubMed ID: 30687994
[TBL] [Abstract][Full Text] [Related]
44. Application of Machine Learning Methods to Predict Non-Alcoholic Steatohepatitis (NASH) in Non-Alcoholic Fatty Liver (NAFL) Patients.
Fialoke S; Malarstig A; Miller MR; Dumitriu A
AMIA Annu Symp Proc; 2018; 2018():430-439. PubMed ID: 30815083
[TBL] [Abstract][Full Text] [Related]
45. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
46. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
[TBL] [Abstract][Full Text] [Related]
47. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Doumas M; Imprialos K; Stavropoulos K; Athyros VG
Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
[TBL] [Abstract][Full Text] [Related]
48. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease.
Haflidadottir S; Jonasson JG; Norland H; Einarsdottir SO; Kleiner DE; Lund SH; Björnsson ES
BMC Gastroenterol; 2014 Sep; 14():166. PubMed ID: 25260964
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
Cusi K; Alkhouri N; Harrison SA; Fouqueray P; Moller DE; Hallakou-Bozec S; Bolze S; Grouin JM; Jeannin Megnien S; Dubourg J; Ratziu V
Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):889-902. PubMed ID: 34560015
[TBL] [Abstract][Full Text] [Related]
50. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
Younossi Z; Stepanova M; Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Schall RA; McColgan B; Subramanian GM; Myers RP; Muir A; Afdhal NH; Bosch J; Goodman Z
J Hepatol; 2018 Dec; 69(6):1365-1370. PubMed ID: 30144554
[TBL] [Abstract][Full Text] [Related]
51. Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital.
Marjot T; Sbardella E; Moolla A; Hazlehurst JM; Tan GD; Ainsworth M; Cobbold JFL; Tomlinson JW
Diabet Med; 2018 Jan; 35(1):89-98. PubMed ID: 29094442
[TBL] [Abstract][Full Text] [Related]
52. Xiaoyao Powder in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Liu N; Yang J; Ma W; Li C; An L; Zhang X; Zou Q
J Ethnopharmacol; 2022 Apr; 288():114999. PubMed ID: 35051605
[TBL] [Abstract][Full Text] [Related]
53. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
[TBL] [Abstract][Full Text] [Related]
54. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
[TBL] [Abstract][Full Text] [Related]
55. Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects.
Newfield RS; Graves CL; Newbury RO; Schwimmer JB; Proudfoot JA; Say DS; Feldstein AE
Pediatr Diabetes; 2019 Feb; 20(1):41-47. PubMed ID: 30467936
[TBL] [Abstract][Full Text] [Related]
56. Chinese Herbal Medicine Decreases Incidence of Cirrhosis in Patients with Non-Alcoholic Fatty Liver Disease in Taiwan: A Propensity Score-Matched Cohort Study.
Huang CY; Wu MY; Wang HC; Liao YC; Tou SI; Yen HR
J Altern Complement Med; 2021 Jul; 27(7):596-605. PubMed ID: 33913734
[No Abstract] [Full Text] [Related]
57. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
Yabiku K
Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
[TBL] [Abstract][Full Text] [Related]
58. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
59. A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?
Vincent RK; Williams DM; Evans M
Diabetes Obes Metab; 2020 Dec; 22(12):2227-2240. PubMed ID: 32945071
[TBL] [Abstract][Full Text] [Related]
60. miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease.
Fernández-Tussy P; Fernández-Ramos D; Lopitz-Otsoa F; Simón J; Barbier-Torres L; Gomez-Santos B; Nuñez-Garcia M; Azkargorta M; Gutiérrez-de Juan V; Serrano-Macia M; Rodríguez-Agudo R; Iruzubieta P; Anguita J; Castro RE; Champagne D; Rincón M; Elortza F; Arslanow A; Krawczyk M; Lammert F; Kirchmeyer M; Behrmann I; Crespo J; Lu SC; Mato JM; Varela-Rey M; Aspichueta P; Delgado TC; Martínez-Chantar ML
Mol Metab; 2019 Nov; 29():40-54. PubMed ID: 31668391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
